JP2019531344A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531344A5 JP2019531344A5 JP2019535993A JP2019535993A JP2019531344A5 JP 2019531344 A5 JP2019531344 A5 JP 2019531344A5 JP 2019535993 A JP2019535993 A JP 2019535993A JP 2019535993 A JP2019535993 A JP 2019535993A JP 2019531344 A5 JP2019531344 A5 JP 2019531344A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- weight
- liquid
- crystals
- water
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201611031045 | 2016-09-12 | ||
| IN201611031045 | 2016-09-12 | ||
| US201662412681P | 2016-10-25 | 2016-10-25 | |
| US62/412,681 | 2016-10-25 | ||
| PCT/IB2017/001312 WO2018047013A1 (en) | 2016-09-12 | 2017-09-12 | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1, 2-dithiole-3-thione, and methods of making and using same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019531344A JP2019531344A (ja) | 2019-10-31 |
| JP2019531344A5 true JP2019531344A5 (enExample) | 2020-11-05 |
Family
ID=60569947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019535993A Pending JP2019531344A (ja) | 2016-09-12 | 2017-09-12 | ４−メチル−５−（ピラジン−２−イル）−３ｈ−１，２−ジチオール−３−チオンの処方物、ならびにそれらの製造方法及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11426403B2 (enExample) |
| EP (1) | EP3509642A1 (enExample) |
| JP (1) | JP2019531344A (enExample) |
| KR (1) | KR102658015B1 (enExample) |
| CN (1) | CN109996562A (enExample) |
| AU (1) | AU2017323504A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7930336B2 (en) | 2006-12-05 | 2011-04-19 | Altera Corporation | Large multiplier for programmable logic device |
| CA3036630A1 (en) * | 2016-09-12 | 2018-03-15 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7067116B1 (en) | 2000-03-23 | 2006-06-27 | Warner-Lambert Company Llc | Fast dissolving orally consumable solid film containing a taste masking agent and pharmaceutically active agent at weight ratio of 1:3 to 3:1 |
| CA2408152A1 (en) | 2000-05-05 | 2001-11-15 | Wisconsin Alumni Research Foundation | Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| US7012148B2 (en) | 2001-09-25 | 2006-03-14 | Trustees Of Dartmouth College | Compositions and methods for thionation during chemical synthesis reactions |
| US7199122B2 (en) | 2001-10-02 | 2007-04-03 | Fox Chase Cancer Center | Methods for inhibiting angiogenesis |
| US20050182128A1 (en) | 2002-02-13 | 2005-08-18 | Stephen Lam | Use of anethole dithiolethione in lung cancer chemoprevention |
| KR100491318B1 (ko) | 2002-11-26 | 2005-05-24 | 씨제이 주식회사 | 올티프라즈(Ｏｌｔｉｐｒａｚ) 제조방법 |
| ZA200604862B (en) | 2003-12-22 | 2007-10-31 | Alcon Inc | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
| KR100629771B1 (ko) * | 2004-01-27 | 2006-09-28 | 씨제이 주식회사 | 결정성이 감소되거나 무정형화된 올티프라즈의 제조방법 |
| PL2486942T3 (pl) * | 2004-11-24 | 2019-05-31 | Meda Pharmaceuticals Inc | Kompozycje zawierające azelastynę oraz sposoby ich stosowania |
| FR2879444B1 (fr) | 2004-12-22 | 2007-05-18 | Oreal | Utilisation d'un compose capable d'augmenter le taux de glutathion dans les melanocytes pour le traitement de la canitie |
| US20070036733A1 (en) | 2005-08-12 | 2007-02-15 | Takasago International Corp. (Usa) | Sensation masking composition |
| BRPI0616821B1 (pt) | 2005-08-15 | 2022-06-07 | Givaudan Sa | Método para proporcionar um efeito refrescante em um produto e produto possuindo um efeito refrescante |
| US7803353B2 (en) | 2006-03-29 | 2010-09-28 | The Procter & Gamble Company | Oral care compositions having improved consumer aesthetics and taste |
| GB0704718D0 (en) | 2007-03-12 | 2007-04-18 | Prendergast Patrick T | Compounds and methods for preventing and treating mucositis |
| WO2008151460A2 (en) | 2007-06-13 | 2008-12-18 | Givaudan Sa | Cooling compounds |
| US20110003747A1 (en) | 2007-07-20 | 2011-01-06 | Coloumbe Pierre A | Use of nrf2 inducers to treat epidermolysis bullosa simplex and related diseases |
| EP2244699A2 (en) | 2008-01-31 | 2010-11-03 | Mcneil-PPC, Inc | Edible film-strips for immediate release of active ingredients |
| US8142806B2 (en) | 2008-03-10 | 2012-03-27 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| US8858995B2 (en) | 2008-03-10 | 2014-10-14 | University Of Louisville Research Foundation, Inc. | Methods and compositions for controlled delivery of phytochemical agents |
| KR101057485B1 (ko) | 2008-08-04 | 2011-08-17 | 서울대학교산학협력단 | 1,2-디티올티온 유도체를 함유하는 엘엑스알-알파 과다발현으로 인한 질병의 예방 및 치료용 약학 조성물 |
| WO2010128026A2 (en) | 2009-05-05 | 2010-11-11 | Givaudan Sa | Organic compounds |
| CN102451469A (zh) * | 2010-10-26 | 2012-05-16 | 沈阳药科大学 | 一类用于难溶性药物纳米系统的高效稳定剂 |
| US10463611B2 (en) * | 2011-06-08 | 2019-11-05 | Sti Pharma, Llc | Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration |
| ES2632443T3 (es) * | 2011-09-22 | 2017-09-13 | Viiv Healthcare Uk Limited | Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH |
| WO2014100403A1 (en) * | 2012-12-19 | 2014-06-26 | Kashiv Pharma, Llc | Supersaturated stabilized nanoparticles for poorly soluble drugs |
| WO2015023889A1 (en) | 2013-08-16 | 2015-02-19 | Luminus Biosciences Inc. | Rapidly-dissolving thin film formulation of water soluble digitalis glycoside for the treatment of congestive heart disease |
| CA2937766A1 (en) | 2014-02-27 | 2015-09-03 | The Procter & Gamble Company | Oral care compositions with a reduced bitter taste perception |
| WO2016207914A2 (en) | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for preparing oltipraz |
| US20160376259A1 (en) * | 2015-06-25 | 2016-12-29 | St Ip Holding Ag | Methods for Preparing Oltipraz |
| ITUB20159655A1 (it) | 2015-12-23 | 2017-06-23 | Bormioli Rocco Spa | Capsula di sicurezza di un contenitore. |
| ITUA20162141A1 (it) | 2016-03-31 | 2017-10-01 | Bormioli Pharma Spa | Capsula di chiusura |
| CA3036630A1 (en) * | 2016-09-12 | 2018-03-15 | St Ip Holding Ag | Formulations of 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, taste-modified formulations, and methods of making and using same |
| KR20180123796A (ko) | 2017-05-10 | 2018-11-20 | 서울대학교산학협력단 | Nrf2-NEMO 경로 활성화를 통한 과중력으로 인한 세포괴사의 억제용 조성물 및 방법 |
-
2017
- 2017-09-12 JP JP2019535993A patent/JP2019531344A/ja active Pending
- 2017-09-12 KR KR1020197010583A patent/KR102658015B1/ko active Active
- 2017-09-12 AU AU2017323504A patent/AU2017323504A1/en not_active Abandoned
- 2017-09-12 CN CN201780069787.9A patent/CN109996562A/zh active Pending
- 2017-09-12 EP EP17808567.6A patent/EP3509642A1/en active Pending
-
2019
- 2019-03-12 US US16/351,058 patent/US11426403B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20230042785A1 (en) | Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery | |
| JP5587198B2 (ja) | タキサン誘導体を含有する、安定性が改良された凍結乾燥医薬組成物、及びその製法 | |
| US20200246278A1 (en) | Injectable diethylstilbestrol nanosuspension formulation | |
| US12403148B2 (en) | PH stabilized ophthalmic compositions | |
| CN102421451A (zh) | 苯达莫司汀环多糖组合物 | |
| Praphanwittaya et al. | Aqueous solubility of kinase inhibitors: I the effect of hydrophilic polymers on their γ-cyclodextrin solubilization | |
| CN108697683A (zh) | 口服紫杉烷组合物和方法 | |
| KR20210044245A (ko) | 주사가능 약학 조성물 및 이의 제조 방법 | |
| JP2020073564A5 (enExample) | ||
| EP4284334A1 (en) | Pharmaceutical composition comprising a diphenylpyrazine derivative | |
| AR098389A1 (es) | Complejos de fulvestrant y sus derivados, proceso para su preparación y composiciones farmacéuticas que los contienen | |
| CN114007588A (zh) | 比拉斯汀的稳定和保存的药物组合物 | |
| Öztürk et al. | Mixed micelles formulation for carvedilol delivery: In-vitro characterization and in-vivo evaluation | |
| JP2019531344A5 (enExample) | ||
| JP6666352B2 (ja) | デュタステリド含有固体分散体及びこれを含む組成物 | |
| US20240058358A1 (en) | Ph stabilized topical ophthlamic compositions | |
| JP2019533008A5 (enExample) | ||
| WO2022061120A1 (en) | Solid dispersions containing amorphous nintedanib, their synthesis and use thereof | |
| ES2893973T3 (es) | Composiciones de múltiples profármacos de aripiprazol | |
| JP7157830B2 (ja) | アリピプラゾールプロドラッグ組成物 | |
| TW201922250A (zh) | 比拉斯汀（ｂｉｌａｓｔｉｎｅ）的水性組成物 | |
| Sigfridsson et al. | Evaluation of exposure properties after injection of nanosuspensions and microsuspenions into the intraperitoneal space in rats | |
| JP2007016024A (ja) | ロフルミラスト点眼液 | |
| JP2024532885A (ja) | 医薬組成物及びその調製方法 | |
| WO2024194449A1 (en) | Pharmaceutical composition comprising a diphenylpyrazine derivative |